Heparin-induced thrombocytopenia: Successful biological and clinical management with lepirudin despite severe renal impairment

• References

• 1 Warkentin TE, Levine MN, Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
• 2 Wallis DE, Workman DL, Lewis BE. et al. Failure of early heparin cessation as treatment for heparin-in-duced thrombocytopenia. Am J Med 1999; 106: 629-635.
• 3 Nowak G. Heparin-induced thrombocytopenia (HIT II) – A drug associated autoimmune disease. Thromb Haemost 2009; 102: 887-891.
• 4 Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95: 967-981.
• 5 Tardy-Poncet B, Wolf M, Lasne D. et al. Danaparoid cross-reactivity with heparin-induced thrombocytopenia antibodies: report of 12 cases. Intensive Care Med 2009; 35: 1449-1453.
• 6 Warkentin TE, Greinacher A, Koster A. et al. American College of Chest Physicians.. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S.
• 7 Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99: 819-829.
• 8 Lubenow N, Eichler P, Lietz T. et al. Hit Investigators Group.. Lepirudin in patients with heparin-induced thrombocytopenia – results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3: 2428-2436.